Back to Search
Start Over
Phase II double-blind randomized study of lonidamine and radiotherapy in epidermoid carcinoma of the lung.
- Source :
-
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 1987 Dec; Vol. 10 (4), pp. 285-90. - Publication Year :
- 1987
-
Abstract
- Patients with non metastatic squamous cell lung cancer were treated with radiotherapy (RT) plus lonidamine (LND) or placebo (PLAC), according to a randomized double-blind study design. Treatment with lonidamine 150 mg t.i.d. (27 patients) or placebo (23 patients) started 3 days before RT, lasted up to 7 months. Partial responses were observed in 14 and 6 patients respectively in the LND + RT and PLAC + RT groups. Statistical analysis of the survival curves showed no significant difference between the LND + RT (median 311 days) and PLAC + RT (median 193 days) groups. Stage III patients survived significantly longer (p less than 0.05) when treated with LND + RT (median 318 days) than with PLAC + RT (median 163 days). No synergistic toxic effects between radiation and LND were noted. To confirm these data a new and larger multicentric study is now in progress.
- Subjects :
- Aged
Antineoplastic Agents
Combined Modality Therapy
Double-Blind Method
Drug Evaluation
Female
Humans
Male
Middle Aged
Carcinoma, Squamous Cell drug therapy
Carcinoma, Squamous Cell mortality
Carcinoma, Squamous Cell radiotherapy
Indazoles therapeutic use
Lung Neoplasms drug therapy
Lung Neoplasms mortality
Lung Neoplasms radiotherapy
Pyrazoles therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0167-8140
- Volume :
- 10
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 3444905
- Full Text :
- https://doi.org/10.1016/s0167-8140(87)80034-8